Trial Profile
A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary) ; DTaP poliovirus vaccine; Hepatitis B vaccine; Measles mumps and rubella virus vaccine; Pneumococcal vaccine conjugate; Rotavirus vaccine; Varicella vaccines
- Indications Meningococcal infections
- Focus Adverse reactions; Registrational
- Acronyms MET41
- Sponsors Sanofi Pasteur
- 31 Mar 2023 Status changed from active, no longer recruiting to completed.
- 03 Jan 2023 Planned End Date changed from 1 Mar 2023 to 1 Apr 2024.
- 03 Jan 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Apr 2024.